Related content

Phase II study of sunitinib malate in patients with recurrent high-grade glioma

By Neyns B.   Sadones J.   Chaskis C.   Dujardin M.   Everaert H.   Lv S.   Duerinck J.   Tynninen O.   Nupponen N.   Michotte A.   Greve J.  

Journal of Neuro-Oncology, Vol. 103, Iss. 3, 2011-07 ,pp. : 491-501

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma

By Abacioglu Ufuk   Caglar Hale   Yumuk Perran   Akgun Zuleyha   Atasoy Beste   Sengoz Meric  

Journal of Neuro-Oncology, Vol. 103, Iss. 3, 2011-07 ,pp. : 585-593

Springer Publishing Company

Access to resources Recommend Favorite

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma

By Verschuere Tina   Van Woensel Matthias   Fieuws Steffen   Lefranc Florence   Mathieu Veronique   Kiss Robert   Van Gool Stefaan   De Vleeschouwer Steven  

Journal of Neuro-Oncology, Vol. 115, Iss. 1, 2013-10 ,pp. : 9-17

Springer Publishing Company

Access to resources Recommend Favorite

Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma

By Duntsch Christopher   Divi Murali   Jones Terreia   Zhou Qihong   Krishnamurthy Mathangi   Boehm Peter   Wood George   Sills Allen   II Bob  

Journal of Neuro-Oncology, Vol. 77, Iss. 2, 2006-04 ,pp. : 143-152

Springer Publishing Company

Access to resources Recommend Favorite

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

By Zuniga Richard   Torcuator Roy   Jain Rajan   Anderson John   Doyle Thomas   Schultz Lonni   Mikkelsen Tom  

Journal of Neuro-Oncology, Vol. 99, Iss. 2, 2010-09 ,pp. : 237-242

Springer Publishing Company

Access to resources Recommend Favorite